Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

A recalled sickle cell drug is drawing new scrutiny from attorneys who say it may have done more harm than good, possibly ...

Pfizer Voluntarily Withdraws Sickle Cell Disease Treatment Oxbryta From Global Market Due To Painful Disease Complication, Deaths (UPDATED) Vandana Singh . Thu, Sep 26, 2024, 10:28 AM 2 min read.

US FDA approves supplemental New Drug Application for expanded indication of Oxbryta® (voxelotor) for children as young as 4 years of age with sickle cell disease. News release. Global Blood ...

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® for the treatment of sickle cell disease at this time, in all markets where it is approved. Pfizer is also ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

Oxbryta, made by Global Blood Therapeutics, ... Many adults with sickle-cell disease have subtle or overt brain damage, which can make it difficult for them to fully understand, ...

First and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy Oxbryta broadly indicated for the treatment of sickle cell disease in adults and children 12 years of ...

Voxelotor (Oxbryta, ... The FDA granted accelerated approval to voxelotor for the treatment of sickle cell disease.The approval applies to use of the therapy for patients aged 12 years and older.

Oxbryta (voxelotor) is a brand-name drug that’s prescribed for sickle cell disease in adults and certain children. As with other drugs, Oxbryta can cause side effects, such as headache ...

In November 2019, the FDA granted accelerated approval to voxelotor (Oxbryta) for adults and pediatric patients 12 years of age and older with sickle cell disease. Price Action: PFE stock is down ...